Therapeutic drug monitoring of β-lactam antibiotics in the critically ill: Direct measurement of unbound drug concentrations to achieve appropriate drug exposures.
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Objectives: To describe the achievement of unbound β-lactam antibiotic concentration targets in a therapeutic drug monitoring (TDM) programme in critically ill patients, and the factors associated with failure to achieve a target concentration. Patients and methods: Plasma samples and clinical data were obtained for analysis from a single centre prospectively. Unbound concentrations of ceftriaxone, cefazolin, meropenem, ampicillin, benzylpenicillin, flucloxacillin and piperacillin were directly measured using ultracentrifugation. Factors associated with the achievement of pharmacokinetic/pharmacodynamic (PK/PD) targets or negative clinical outcomes were evaluated with binomial logistic regression. Results: TDM data from 330 patients, and 369 infection episodes, were included. The range of doses administered was 99.4% ± 45.1% relative to a standard daily dose. Dose increases were indicated in 33.1% and 63.4% of cases to achieve PK/PD targets of 100% fT>MIC and 100% fT>4×MIC, respectively. Dose reduction was indicated in 17.3% of cases for an upper PK/PD threshold of 100% fT>10×MIC. Higher protein bound β-lactams (ceftriaxone and benzylpenicillin) had better therapeutic target attainment (P < 0.01), but were prone to excessive dosing. Augmented renal clearance (calculated CLCR >130 mL/min) increased the odds of failure to achieve 100% fT>MIC and 100% fT>4×MIC (OR 2.47 and 3.05, respectively; P < 0.01). Conclusions: Measuring unbound concentrations of β-lactams as part of a routine TDM programme is feasible and demonstrates that a large number of critically ill patients do not achieve predefined PK/PD targets. The clinical significance of this finding is unknown due to the lack of correlation between PK/PD findings and clinical outcomes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Applying a PK/PD approach to antibiotic dosing requires support from knowledgeable clinician team members [254], use of a patient population-specific guideline document [255], use of therapeutic drug monitoring [256], and/or use of dosing software [238, 248].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [256]
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Kumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109
International Study of the Prevalence and Outcomes of Infection in Intensive Care Units
Vincent, J.-L. (2009) · JAMA · doi:10.1001/jama.2009.1754 · Cited by 3,618
Sepsis in European intensive care units: Results of the SOAP study*
Vincent, J.-L., Sakr, Y., Sprung, C. L., Ranieri, V. M., Reinhart, K., Gerlach, H., Moreno, R., Carlet, J., Le Gall, J.-R., & Payen, D. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000194725.48928.3a · Cited by 2,836
Roberts, J. A., Paul, S. K., Akova, M., Bassetti, M., De Waele, J. J., Dimopoulos, G., Kaukonen, K.-M., Koulenti, D., Martin, C., Montravers, P., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu027 · Cited by 1,090
Self-citationRoberts, J. A., Abdul-Aziz, M. H., Lipman, J., Mouton, J. W., Vinks, A. A., Felton, T. W., Hope, W. W., Farkas, A., Neely, M. N., Schentag, J. J., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70036-2 · Cited by 1,046
Self-citationAntimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930
Principles of antibacterial dosing in continuous renal replacement therapy
Choi, G., Gomersall, C. D., Tian, Q., Joynt, G. M., Freebairn, R., & Lipman, J. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181aab3d0 · Cited by 334
Self-citationTherapeutic drug monitoring of β-lactams in critically ill patients: proof of concept
Roberts, J. A., Ulldemolins, M., Roberts, M. S., McWhinney, B., Ungerer, J., Paterson, D. L., & Lipman, J. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.06.008 · Cited by 334
Self-citationRole of pharmacokinetics in the outcome of infections
Drusano, G. L. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.3.289 · Cited by 330
Abdul-Aziz, M. H., Sulaiman, H., Mat-Nor, M.-B., Rai, V., Wong, K. K., Hasan, M. S., Abd Rahman, A. N., Jamal, J. A., Wallis, S. C., Lipman, J., et al. (2016) · Intensive Care Medicine · doi:10.1007/s00134-015-4188-0 · Cited by 308
Self-citationUdy, A. A., Baptista, J. P., Lim, N. L., Joynt, G. M., Jarrett, P., Wockner, L., Boots, R. J., & Lipman, J. (2014) · Critical Care Medicine · doi:10.1097/ccm.0000000000000029 · Cited by 280
Self-citationPharmacodynamics of cefepime in patients with Gram-negative infections
Tam, V. H. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf130 · Cited by 262
Wong, G., Briscoe, S., Adnan, S., McWhinney, B., Ungerer, J., Lipman, J., & Roberts, J. A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00951-13 · Cited by 229
Self-citationHuttner, A., Von Dach, E., Renzoni, A., Huttner, B. D., Affaticati, M., Pagani, L., Daali, Y., Pugin, J., Karmime, A., Fathi, M., et al. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.12.017 · Cited by 220
Baptista, J. P., Udy, A. A., Sousa, E., Pimentel, J., Wang, L., Roberts, J. A., & Lipman, J. (2011) · Critical Care · doi:10.1186/cc10262 · Cited by 211
Self-citationLamoth, F., Buclin, T., Pascual, A., Vora, S., Bolay, S., Decosterd, L. A., Calandra, T., & Marchetti, O. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01595-08 · Cited by 182
Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure
Martínez-Rodríguez, J. E., Barriga, F. J., Santamaria, J., Iranzo, A., Pareja, J. A., Revilla, M., & dela Rosa, C. R. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00767-7 · Cited by 163
for the EPIC II Investigators, Waele, J. J. D., Lipman, J., Sakr, Y. L., Marshall, J. C., Vanhems, P., Groba, C. B., Léone, M., & Vincent, J. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-420 · Cited by 146
Self-citationBriscoe, S., McWhinney, B. C., Lipman, J., Roberts, J. A., & Ungerer, J. P. J. (2012) · Journal of Chromatography B · doi:10.1016/j.jchromb.2012.09.016 · Cited by 140
Self-citationUdy, A. A., Lipman, J., Jarrett, P., Klein, K., Wallis, S. C., Patel, K., Kirkpatrick, C. M., Kruger, P. S., Paterson, D. L., Roberts, M. S., et al. (2015) · Critical Care · doi:10.1186/s13054-015-0750-y · Cited by 138
Self-citationMachen, A. J., Drake, T., & Wang, Y. F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087870 · Cited by 129
Udy, A. A., Dulhunty, J. M., Roberts, J. A., Davis, J. S., Webb, S. A. R., Bellomo, R., Gomersall, C. D., Shirwadkar, C., Eastwood, G. M., Myburgh, J., et al. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.12.022 · Cited by 123
Self-citationUlldemolins, M., Roberts, J. A., Wallis, S. C., Rello, J., & Lipman, J. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq184 · Cited by 117
Self-citationProspective monitoring of cefepime in intensive care unit adult patients
Chapuis, T. M., Giannoni, E., Majcherczyk, P. A., Chioléro, R., Schaller, M.-D., Berger, M. M., Bolay, S., Décosterd, L. A., Bugnon, D., & Moreillon, P. (2010) · Critical Care · doi:10.1186/cc8941 · Cited by 102
Jamal, J.-A., Economou, C. J. P., Lipman, J., & Roberts, J. A. (2012) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32835685ad · Cited by 96
Self-citationPea, F., Viale, P., Cojutti, P., & Furlanut, M. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01291-12 · Cited by 78
Jamal, J., Nor, M. B. M., Nor, F. S. M., Udy, A. A., Wallis, S. C., Lipman, J., & Roberts, J. A. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.09.009 · Cited by 72
Self-citationTDM-Guided Therapy with Daptomycin and Meropenem in a Morbidly Obese, Critically Ill Patient
Pea, F., Cojutti, P. G., Sbrojavacca, R., Cadeo, B., Cristini, F., Bulfoni, A., & Furlanut, M. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1p745 · Cited by 60
Rapid susceptibility profiling of carbapenem-resistant Klebsiella pneumoniae
Mulroney, K. T., Hall, J. M., Huang, X., Turnbull, E., Bzdyl, N. M., Chakera, A., Naseer, U., Corea, E. M., Ellington, M. J., Hopkins, K. L., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-02009-3 · Cited by 54
Carlier, M., Carrette, S., Stove, V. V., Verstraete, A., & Waele, J. J. D. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.01.028 · Cited by 53
Pharmacokinetic-Pharmacodynamic-Model-Guided Doripenem Dosing in Critically Ill Patients
Samtani, M. N., Flamm, R. K., Kaniga, K., & Nandy, P. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01843-09 · Cited by 50
Lonsdale, D. O., Udy, A. A., Roberts, J. A., & Lipman, J. (2012) · Journal of neurosurgery · doi:10.3171/2012.10.jns12883 · Cited by 49
Self-citationBarletta, J. F., Mangram, A. J., Byrne, M., Hollingworth, A. K., Sucher, J. F., Ali-Osman, F. R., Shirah, G. R., & Dzandu, J. K. (2016) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000001211 · Cited by 49
Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients
Dhaese, S. A. M., Roberts, J. A., Carlier, M., Verstraete, A., Stove, V. V., & Waele, J. J. D. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.12.015 · Cited by 48
Self-citationSmith, N. L., Freebairn, R. C., Park, M. A. J., Wallis, S. C., Roberts, J. A., & Lipman, J. (2012) · Critical Care and Resuscitation · doi:10.1016/s1441-2772(23)01773-8 · Cited by 41
Self-citationAdnan, S., Paterson, D. L., Lipman, J., Kumar, S., Li, J., Rudd, M., & Roberts, J. A. (2012) · Surgical Infections · doi:10.1089/sur.2011.046 · Cited by 36
Self-citationWong, G., Farkas, A., Sussman, R., Daróczi, G., Hope, W. W., Lipman, J., & Roberts, J. A. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04001-14 · Cited by 31
Self-citationShotwell, M. S., Nesbitt, R., Madonia, P. N., Gould, E. R., Connor, M. J., Jr., Salem, C., Aduroja, O. A., Amde, M., Groszek, J. J., Wei, P., et al. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10260915 · Cited by 29
Cited by
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Self-citationSurviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Self-citationAntimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
Abdul-Aziz, M. H., Alffenaar, J.-W. C., Bassetti, M., Bracht, H., Dimopoulos, G., Marriott, D., Neely, M. N., Paiva, J.-A., Pea, F., Sjovall, F., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06050-1 · Cited by 1,081
Self-citationGuilhaumou, R., Benaboud, S., Bennis, Y., Dahyot-Fizelier, C., Dailly, E., Gandia, P., Goutelle, S., Lefeuvre, S., Mongardon, N., Roger, C., et al. (2019) · Critical Care · doi:10.1186/s13054-019-2378-9 · Cited by 543
Bloodstream infections in critically ill patients: an expert statement
Timsit, J.-F., Ruppé, E., Barbier, F., Tabah, A., & Bassetti, M. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05950-6 · Cited by 448
Metadata
- Authors
- Wong, G., Briscoe, S., McWhinney, B., Ally, M., Ungerer, J., Lipman, J., & Roberts, J. A.
- Affiliations
- The University of Queensland (AU)
- Chemical Pathology, Pathology Queensland, Brisbane, Queensland, Australia
- Corresponding author
- Roberts, Jason A
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-08-17
- Volume
- 73
- Issue
- 11
- Pages
- 3087-3094
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2887835365
- Cited by
- 169
- References
- 40
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 28 · 2023: 32 · 2022: 34 · 2021: 25 · 2020: 21 · 2019: 10 · 2018: 2
- FWCI
- 9.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Antimicrobial Chemotherapy (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Health and Medical Research Council of Australia (APP1117065)
- Australian National Health and Medical Research Council for Centre of Research Excellence (APP1099452)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- beta-lactam antibiotics, therapeutic drug monitoring, unbound drug concentration, critically ill patients, PK/PD targets, ceftriaxone, cefazolin, meropenem, ampicillin, penicillin G, flucloxacillin, piperacillin, protein binding, renal clearance, dose adjustment, infection treatment
- MeSH terms
- Meropenem, Adult, Aged, Anti-Bacterial Agents, Ceftriaxone, Female, Humans, Male, Microbial Sensitivity Tests, Middle Aged, Piperacillin, Prospective Studies, Logistic Models, Critical Illness, Treatment Outcome, Drug Monitoring, beta-Lactams
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.